



UNIVERSITY
OF
CALIFORNIA

An Overview of the UC Drug Discovery Consortium

Joe Wagner, Ph.D.

Executive Director, UC DDC

joseph.wagner@ucsf.edu

“Building a UC Drug Discovery Community”

UC DDC

UC Drug Discovery Consortium (UC DDC)

- The University of California Drug Discovery Consortium (UC DDC) is a multi-campus initiative created by the University of California Biomedical Research Acceleration, Integration & Development (UC BRAID) Drugs, Devices, Diagnostics Development (D4) group
- The development of the UC DDC is supported by a 3-year, \$2M Multi-Campus Research Proposal Initiative grant (MRPI) from the UC Office of the President.
- The UC DDC currently involves representatives from UC San Francisco, UC Los Angeles, UC Irvine, UC Davis and UC San Diego. In the future, we hope to include all UC Campuses.

“Building a UC Drug Discovery Community”

UC-DDC Governance & Team

Executive Committee

- **Melanie Cocco, Ph.D.**, UC Irvine Site Lead & Chairperson, Year Two
- **Robert Damoiseaux, Ph.D.**, UC Los Angeles Site Lead
- **Michael Gilson, M.D., Ph.D.** UC San Diego Site Lead
- **Michael Rogawski, M.D.** UC Davis Site Lead

Program Management

- **Joseph Wagner, Ph.D.**, Executive Director UC DDC and Interim UCSF Site Lead
- **Haim Weizman, Ph.D.**, Lead for Education, UC San Diego

“Building a UC Drug Discovery Community”

UC-DDC Aims

Support the development of therapeutics with mentoring & pilot funding

Strengthen drug discovery education & training

Expedite access to existing drug discovery related core facilities across the UC system

Build partnerships with industry and foundations to increase support for projects and develop sustainability


“Building a UC Drug Discovery Community”

Seed Grant Review & Award Process, Year One

- Step One: Request for Proposals
 - Issued in July, 2017
 - Projects from Compound Screening to Pre-Clinical Studies eligible for funding
- Step Two: Letter's of Intent Submitted
 - 110 Eligible projects submitted across 5 sites
- Step Three: LOI's Reviewed & Finalists Selected
 - UC-DDC Site Lead PI's review LOI's, 3 finalists/site selected
 - Full applications requested from 15 finalists
- Step Four: Peer Review of Finalist Applications
 - At least 2 reviewers per application with at least 1 industry reviewer
 - Scored areas: Unmet Need, Innovation, Competition, Work Plan, Investigator, IP
- Step Five: Award of Seed Grants
 - Final review of scores by UC-DDC Executive Committee
 - Awards of up to \$50,000 made


“Building a UC Drug Discovery Community”

Breakdown of Seed Grant Applications by Disease Area




“Building a UC Drug Discovery Community”

Breakdown of Seed Grant Applications by Development Stage




“Building a UC Drug Discovery Community”

Breakdown of Seed Grant Applications by Drug Class



“Building a UC Drug Discovery Community”

Breakdown of Seed Grant Applications by UC Campus



“Building a UC Drug Discovery Community”

Final Seed Grant Awards, Year One

<u>Awardee</u>	<u>Project Title</u>
Peter Bowers, Ph.D. UCLA	Development of a Pleiotrophin Monoclonal Antibody to Reduce Leukemic Stem Cell Growth
Gino Cortopassi, Ph.D. UC Davis	Shc inhibitors for Fatty Liver Disease and Alzheimer's
Alessandra Franco, MD, Ph.D. UCSD	Pre-clinical studies to rank 3-5 immunodominant peptide epitopes derived from the heavy constant region of immunoglobulins (Fc) that stimulate natural regulatory T cells
Jason Gestwicki, Ph.D. UCSF	Design of Pin1 Inhibitors
Tannishtha Reya, Ph.D. UCSD	Targeting Stem Cell Signals in Cancer Development and Progression
Christopher Vanderwal, Ph.D. UC Irvine	Development of Small-Molecule Inhibitors of the Myc/Max Protein Interaction

“Building a UC Drug Discovery Community”

Drug Discovery Education & Training

- **Hands-on Training in Core Methods and Principles**
 - Post-docs and graduate students eligible to apply
 - 15 total participants selected (3/campus)
 - Lectures and practical laboratory exercises
- **Two workshops held to date**
 - Assay Development for Drug Discovery @ UCLA
 - Drug Metabolism and Pharmacokinetics @ UCSD
- **Public Lectures:** Drug Discovery and the UC's presented at UCSD through Osher Lifelong Learning Institute

“Building a UC Drug Discovery Community”

UCCore

TARGET NOMINATION ▼

HIT GENERATION ▼

LEAD OPTIMIZATION ▼

PRECLINICAL DEVELOPMENT ▼

CLINICAL DEVELOPMENT ▼

UNIVERSITY
OF
CALIFORNIA

UC-CORE enables drug discovery by connecting researchers with relevant resources across the entire University of California network.

How to use

Events

Contact/Partners

Build partnerships with industry and develop sustainability

Current Proposed Model

- **Industrial Membership Rights & Obligations**
 - Various levels of membership & annual dues
 - Ability to review DDC funded work at defined frequency
 - Rights to non-exclusive option on work funded with industry dues
 - Rights to exclusive option if no non-exclusive options exercised
- **UC-DDC Roles & Responsibilities**
 - Provide access to innovation
 - Serve as entry portal to UC drug discovery and drug development activities
 - Provide project management & expertise to support funded research

“Building a UC Drug Discovery Community”

Looking Forward

– Multi-campus buy-in of model

- Key terms agreed to by multiple UC's
- Execution of Consortium Agreement across DDC UC's expected soon
- Expansion to include other UC's

– Engagement of Industry Partners

- Discussions with potential industry and technology partners well underway
- Expectation of multiple partners onboard for first "partnered" year of DDC

– Full consortium operating during Year Three

"Building a UC Drug Discovery Community"

UC DDC Gratefully Acknowledges

- **UC Office of the President**
- **Our Seed Grant Reviewers**
- **UC Offices of Technology Management and Innovation Ventures**
- **UC BRAID & CNSI Staff**

“Building a UC Drug Discovery Community”

How to Contact Us

www.ucdrugdiscovery.org

Joseph.Wagner@UCSF.edu

“Building a UC Drug Discovery Community”